Cargando…

Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xiangyu, Zhao, Ping, Lin, Jierou, Chen, Kun, Shen, Jianliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344729/
https://www.ncbi.nlm.nih.gov/pubmed/37457134
http://dx.doi.org/10.20517/cdr.2023.16
_version_ 1785072923459977216
author Sun, Xiangyu
Zhao, Ping
Lin, Jierou
Chen, Kun
Shen, Jianliang
author_facet Sun, Xiangyu
Zhao, Ping
Lin, Jierou
Chen, Kun
Shen, Jianliang
author_sort Sun, Xiangyu
collection PubMed
description Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments.
format Online
Article
Text
id pubmed-10344729
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-103447292023-07-15 Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system Sun, Xiangyu Zhao, Ping Lin, Jierou Chen, Kun Shen, Jianliang Cancer Drug Resist Review Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments. OAE Publishing Inc. 2023-06-20 /pmc/articles/PMC10344729/ /pubmed/37457134 http://dx.doi.org/10.20517/cdr.2023.16 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Sun, Xiangyu
Zhao, Ping
Lin, Jierou
Chen, Kun
Shen, Jianliang
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title_full Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title_fullStr Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title_full_unstemmed Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title_short Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
title_sort recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344729/
https://www.ncbi.nlm.nih.gov/pubmed/37457134
http://dx.doi.org/10.20517/cdr.2023.16
work_keys_str_mv AT sunxiangyu recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem
AT zhaoping recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem
AT linjierou recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem
AT chenkun recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem
AT shenjianliang recentadvancesinaccesstoovercomecancerdrugresistancebynanocarrierdrugdeliverysystem